Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283153 | 0.81 | CCR5 (0.44) | CCR5CTSLCTSKCXCR3CTSS | |
| SCHEMBL5528940 | 0.74 | CCR5 (0.39) | CCR5CTSKCTSSKCNH2NPSR1 | |
| SCHEMBL13929428 | 0.72 | LMNA (0.58) | CTSLCTSKCTSSMEN1KMT2A | |
| SCHEMBL14011507 | 0.72 | LMNA (0.58) | CTSLCTSKCTSSMEN1KMT2A | |
| SCHEMBL13996047 | 0.72 | LMNA (0.58) | CTSLCTSKCTSSMEN1KMT2A | |
| SCHEMBL15311487 | 0.70 | CTSK (0.51) | CTSLCTSKCTSSMEN1KMT2A | |
| SCHEMBL13742885 | 0.70 | CCR5 (0.73) | CCR5KCNH2 | |
| SCHEMBL13743089 | 0.70 | CCR5 (0.49) | CCR5KCNH2 | |
| SCHEMBL13326683 | 0.68 | CCR5 (0.50) | CCR5CTSKCTSS | |
| SCHEMBL14440789 | 0.68 | CCR5 (0.50) | CCR5CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | CCR5 1/4885CTSL 1986/4885CTSK 2833/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | CCR5 1/4885CTSL 1986/4885CTSK 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.